Texte Alternatif

Trusted by leading brands around the world, Activ-Vial will be produced at the company’s facility in Guangzhou, providing a best-in-class offering for the country’s growing diagnostics market, particularly for patients with diabetes conditions where blood glucose monitoring is a critical component of care.

By locally manufacturing Activ-Vial, Aptar CSP Technologies will bring production closer to the local customer, mitigating supply chain disruptions, and more importantly, providing an optimal solution to the local diabetes patient. The move is a key component of the company’s strategic effort to significantly expand its market presence in China.

“This latest investment in local production expansion reflects our continued commitment to serving the China market,” said Badre Hammond, VP Global Commercial Operations, Aptar CSP Technologies. “This initiative not only represents an investment in the markets and communities we serve, but allows us to leverage local supply chains, improving our cost structure and sustainability of operations.”

Aptar CSP Technologies’ Activ-Vial™ solution features the company’s proprietary 3-Phase Activ-Polymer™ platform technology fully integrated into the vial, creating a microclimate that protects against moisture and other environmental conditions that can impact diabetes test strip stability. Unlike traditional packaging options, this technology co-molds highly-engineered active particles into the vial, completely surrounding the product to scavenge moisture before it ever reaches the contents inside. Additionally, the company’s patented “close in the mold” technology ensures a moisture-tight seal that maintains its integrity throughout shelf life and patient use life to deliver greater product stability.

All rights reserved except agreement written by Emballage Digest or mention of the magazine